BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 26774923)

  • 21. Synthesis, hypoglycaemic, hypolipidemic and PPARγ agonist activities of 5-(2-Alkyl/aryl-6-Arylimidazo[2,1-b][1,3,4]thiadiazol-5-yl)methylene-1,3-thiazolidinediones.
    Khazi MI; Belavagi NS; Kim KR; Gong YD; Khazi IA
    Chem Biol Drug Des; 2013 Aug; 82(2):147-55. PubMed ID: 23581650
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ligands for the Nuclear Peroxisome Proliferator-Activated Receptor Gamma.
    Sauer S
    Trends Pharmacol Sci; 2015 Oct; 36(10):688-704. PubMed ID: 26435213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. L312, a novel PPARγ ligand with potent anti-diabetic activity by selective regulation.
    Xie X; Zhou X; Chen W; Long L; Li W; Yang X; Li S; Wang L
    Biochim Biophys Acta; 2015 Jan; 1850(1):62-72. PubMed ID: 25305559
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Free Fatty Acid Receptor 1 (FFAR1) as an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges.
    Li Z; Xu X; Huang W; Qian H
    Med Res Rev; 2018 Mar; 38(2):381-425. PubMed ID: 28328012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis, characterization, biological evaluation and docking of coumarin coupled thiazolidinedione derivatives and its bioisosteres as PPARγ agonists.
    Shukla S; Kumar P; Das N; Moorthy NS; Shrivastava SK; Trivedi P; Srivastava RS
    Med Chem; 2012 Sep; 8(5):834-45. PubMed ID: 22741802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
    Tjokroprawiro A
    Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective targeting of PPARγ by the natural product chelerythrine with a unique binding mode and improved antidiabetic potency.
    Zheng W; Qiu L; Wang R; Feng X; Han Y; Zhu Y; Chen D; Liu Y; Jin L; Li Y
    Sci Rep; 2015 Jul; 5():12222. PubMed ID: 26183621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of thiazolidine-2,4-dione/biphenylcarbonitrile hybrid as dual PPAR α/γ modulator with antidiabetic effect: in vitro, in silico and in vivo approaches.
    Hidalgo-Figueroa S; Ramírez-Espinosa JJ; Estrada-Soto S; Almanza-Pérez JC; Román-Ramos R; Alarcón-Aguilar FJ; Hernández-Rosado JV; Moreno-Díaz H; Díaz-Coutiño D; Navarrete-Vázquez G
    Chem Biol Drug Des; 2013 Apr; 81(4):474-83. PubMed ID: 23289972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis, and biological evaluation of novel dual FFA1 (GPR40)/PPARδ agonists as potential anti-diabetic agents.
    Li Z; Hu L; Wang X; Zhou Z; Deng L; Xu Y; Zhang L
    Bioorg Chem; 2019 Nov; 92():103254. PubMed ID: 31518760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and evaluation of new 1,2,4-oxadiazole based trans- acrylic acid derivatives as potential PPAR-alpha/gamma dual agonist.
    Kaur P; Bhat ZR; Bhat S; Kumar R; Kumar R; Tikoo K; Gupta J; Khurana N; Kaur J; Khatik GL
    Bioorg Chem; 2020 Jul; 100():103867. PubMed ID: 32353564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of quinazolin-4(3H)-one derivatives as potential PPARγ and SUR agonists.
    Ibrahim MK; Eissa IH; Alesawy MS; Metwaly AM; Radwan MM; ElSohly MA
    Bioorg Med Chem; 2017 Sep; 25(17):4723-4744. PubMed ID: 28720328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis, molecular docking and anti-diabetic evaluation of 2,4-thiazolidinedione based amide derivatives.
    Naim MJ; Alam MJ; Nawaz F; Naidu VGM; Aaghaz S; Sahu M; Siddiqui N; Alam O
    Bioorg Chem; 2017 Aug; 73():24-36. PubMed ID: 28582649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM; Schiffrin EL
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions.
    Schopfer FJ; Cole MP; Groeger AL; Chen CS; Khoo NK; Woodcock SR; Golin-Bisello F; Motanya UN; Li Y; Zhang J; Garcia-Barrio MT; Rudolph TK; Rudolph V; Bonacci G; Baker PR; Xu HE; Batthyany CI; Chen YE; Hallis TM; Freeman BA
    J Biol Chem; 2010 Apr; 285(16):12321-33. PubMed ID: 20097754
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhancing insulin sensitivity by dual PPARγ partial agonist, β-catenin inhibitor: Design, synthesis of new αphthalimido-o-toluoyl2-aminothiazole hybrids.
    Mourad AAE; Mourad MAE
    Life Sci; 2020 Oct; 259():118270. PubMed ID: 32814067
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and biological activity of [[(heterocycloamino)alkoxy] benzyl]-2,4-thiazolidinediones as PPARgamma agonists.
    Jeon R; Kim YJ; Cheon Y; Ryu JH
    Arch Pharm Res; 2006 May; 29(5):394-9. PubMed ID: 16756084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thiazolidinedione derivatives as PTP1B inhibitors with antihyperglycemic and antiobesity effects.
    Bhattarai BR; Kafle B; Hwang JS; Khadka D; Lee SM; Kang JS; Ham SW; Han IO; Park H; Cho H
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6161-5. PubMed ID: 19783142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new class of non-thiazolidinedione, non-carboxylic-acid-based highly selective peroxisome proliferator-activated receptor (PPAR) γ agonists: design and synthesis of benzylpyrazole acylsulfonamides.
    Rikimaru K; Wakabayashi T; Abe H; Imoto H; Maekawa T; Ujikawa O; Murase K; Matsuo T; Matsumoto M; Nomura C; Tsuge H; Arimura N; Kawakami K; Sakamoto J; Funami M; Mol CD; Snell GP; Bragstad KA; Sang BC; Dougan DR; Tanaka T; Katayama N; Horiguchi Y; Momose Y
    Bioorg Med Chem; 2012 Jan; 20(2):714-33. PubMed ID: 22209730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis.
    Wang M; Tafuri S
    J Cell Biochem; 2003 May; 89(1):38-47. PubMed ID: 12682906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.
    Henry JR; Li Y; Warshawsky AM; Brozinick JT; Hawkins ED; Misener EA; Briere DA; Montrose-Rafizadeh C; Zink RW; Yumibe NP; Ajamie RT; Wilken B; Devanarayan V
    Bioorg Med Chem Lett; 2006 Dec; 16(24):6293-7. PubMed ID: 17005393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.